Grünenthal announced today that the company successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist. In the trial, which involved 113 healthy ...

Welcome - Welcome to our sixth issue of 2026 of The Health Record -- our healthcare law insights e-newsletter. Errors ...

Spread the love“`html When it comes to understanding how we learn and develop cognitively, few theories have had as profound ...

The court upheld state laws in West Virginia and Idaho barring the participation of transgender female athletes from girls’ ...

We have updated our Privacy Policy. Please review to learn more. By continuing to use our services, you agree to these updates. Two soldiers deployed as part of a ...